Determination of Vancomycin in Human Serum by Cyclodextrin-Micellar Electrokinetic Capillary Chromatography (CD-MEKC) and Application for PDAP Patients.

Jiajing Wang,Guorong Fan,Yuqing Cao,Tingting Zhou,Yuefen Lou,Shuowen Wang,Shengyuan Wu,Xin Zhao

doi:10.3390/molecules22040538

Abstract

A simple and sensitive cyclodextrin-micellar electrokinetic capillary chromatography (CD-MEKC) method with UV detection was developed and validated for the determination of vancomycin (VCM) in serum. The separation was achieved in 14 min at 25 °C with a fused-silica capillary column of 40.2 cm × 75 μm i.d. (effective length 30.2 cm) and a run buffer containing 25 mM borate buffer with 50 mM sodium dodecylsulfonate (SDS) (pH 9.5) and 2% sulfobutyl-β-cyclodextrin (sulfobutyl-β-CD). Under optimal conditions for biological samples, good separations with high efficiency and short analysis time were achieved. Several parameters affecting the drug separation from biological matrices were studied, including buffer types, concentrations, and pHs. The methods were validated over the range of 0.9998–99.98 µg/mL. Calibration curves of VCM also showed good linearity (r2 > 0.999). Intra- and interday precisions (relative standard deviation, RSD) were less than 5.80% and 7.38%, and lower limit of quantification (LLOQ) were lower than 1.0 μg/mL. The mean recoveries ranged between 84.03% and 91.69%. The method was successfully applied for monitoring VCM concentrations in serum of patients with peritoneal dialysis-associated peritonitis (PDAP). The assay should be applicable to pharmacokinetic studies and routine therapeutic drug monitoring of this drug in serum.

Highlights

Peritoneal dialysis-associated peritonitis (PDAP) is a serious complication in peritoneal dialysis patients
The current increased as the buffer concentration increased, which led to more joule heating and longer analysis time
MTX is an important chemotherapeutic agent which was used in this study as internal standard (IS)

Summary

Introduction

Peritoneal dialysis-associated peritonitis (PDAP) is a serious complication in peritoneal dialysis patients. It is important to reduce the risk of peritoneal dialysis-associated infection. Molecules 2017, 22, 538 and therapy against infections by Gram-positive bacteria, including methicillin-staphylococcus aureus (MRSA) [1,2]. The International Society for Peritoneal Dialysis (ISPD) recommended VCM for the Molecules. 2017, 22,caused treatment of PDAP by infection with MRSA and other Gram-positive bacteria [3]. Serum-level monitoring of VCM is necessary to ensure adequate therapeutic concentrations while prophylaxis and therapy against infections by Gram-positive bacteria, including methicillinavoiding toxic accumulations. Several methods for staphylococcus aureus (MRSA) [1,2]. The International Society for Peritoneal Dialysis (ISPD)

Methods

Results

Conclusion